Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis

详细信息    查看全文

• 作者：Sung-Yeon Cho ; MD¹ ; ² ; Dong-Gun Lee ; MD ; PhD¹ ; ² ; ³ ; ^{symonlee@catholic.ac.kr" class="auth_mail" title="E-mail the corresponding author} ; Jae-Ki Choi ; MD¹ ; ² ; Hyo-Jin Lee ; MD¹ ; ² ; Si-Hyun Kim ; MD ; PhD¹ ; ² ; Sun-Hee Park ; MD ; PhD ; MPH¹ ; ² ; Su-Mi Choi ; MD ; PhD¹ ; ² ; Jung-Hyun Choi ; MD ; PhD¹ ; ² ; Jin-Hong Yoo ; MD ; PhD¹ ; ² ; Yoo-Jin Kim ; MD ; PhD³ ; Hee-Je Kim ; MD ; PhD³ ; Woo-Sung Min ; MD ; PhD³ ; Heejung Back⁴ ; Sukhyun Kang⁴ ; ⁵ ; Eui-Kyung Lee ; PhD⁵
• 关键词：acute myeloid leukemia ; antibiotic prophylaxis ; cost&ndash ; benefit analysis ; myelodysplastic syndromes ; posaconazole
• 刊名：Clinical Therapeutics
• 出版年：2015
• 出版时间：1 September 2015
• 年：2015
• 卷：37
• 期：9
• 页码：2019-2027
• 全文大小：238 K

文摘

Posaconazole is effective for the prophylaxis of invasive fungal infections (IFIs) in patients with acute myeloid leukemia or myelodysplastic syndrome during remission induction chemotherapy. However, a cost–benefit analysis of posaconazole versus fluconazole or itraconazole has not been conducted in Korea.

Methods

We retrospectively reviewed data for all consecutive patients who received primary antifungal prophylaxis during remission induction chemotherapy in our acute myeloid leukemia/myelodysplastic syndrome cohort from December 2010 to November 2013. Patient characteristics and factors known as a risk of IFI were matched with propensity score analysis. We evaluated the medical cost according to the prophylactic antifungal agents (posaconazole vs fluconazole/itraconazole), the development of breakthrough IFIs, and survival status after propensity score matching in a 1:1 ratio.

Findings

Of the 419 baseline patients, 100 patients in each group were analyzed after matching. A significant decrease was found in the development of breakthrough proven or probable IFIs (3.0% vs 14.0%; P = 0.009) and the rate of empirical antifungal therapy (EAFT) (12.0% vs 46.0%; P < 0.001) in the posaconazole group. Total in-hospital medical costs per patient were not statistically different between posaconazole and fluconazole/itraconazole prophylaxis. However, the daily medical cost was lower for posaconazole prophylaxis, resulting in a total daily cost savings of $72 (鈧?9,458) per patient (P = 0.002). In the cases of breakthrough proven/probable IFIs, EAFT, and in-hospital deaths, the total medical costs per patient were significantly higher than in nonproven/probable IFIs, non-EAFT, and in-hospital survivors, as much as $7,916 (鈧?,700,758), $4605 (鈧?,062,529), and $11,134 (鈧?2,238,422), respectively. Costs for the antifungal agent used in targeted or empirical therapy were lower in the posaconazole group, resulting in a savings of $697 (鈧?66,347) per patient (P < 0.001).

Implications

Posaconazole appears to be cost beneficial for primary antifungal prophylaxis in high-risk patients with hematologic malignancy, at a single center, in Korea. Cost–benefit is closely related with clinical outcomes, including breakthrough IFI development, EAFT, and survival status.